Presentations
Posters and talks from scientific meetings, newest first.
-
First-in-Human Phase 1 Study of GTA182, a Novel MTA-Cooperative PRMT5 Inhibitor, in Patients with MTAP-Deleted Advanced Non-Small Cell Lung Cancer
Late-breaking mini oral LBA14, presented by Shun Lu, MD, PhD
-
GTA182: A potentially best-in-class, MTA-cooperative inhibitor for MTAP-deleted advanced solid tumors
Abstract 4229
-
Targeting the mitotic kinesin, KIF18A, in chromosomally unstable cancers
Abstract 4965
-
Defining activity and patient selection of a novel CDK7 inhibitor, GTAEXS-617, through AI-supported primary cancer tissue profiling
Abstract 124
-
AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7
Abstract 3930
Earlier presentations are shown as given. Programs may have since changed name or owner.



